Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Gains from Investment Securities: 2017-2025

Historic Gains from Investment Securities for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Jun 2025 value amounting to -$4.1 million.

  • Crinetics Pharmaceuticals' Gains from Investment Securities rose 70.08% to -$4.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $72.1 million, marking a year-over-year increase of 123.01%. This contributed to the annual value of $13.7 million for FY2024, which is 8.23% up from last year.
  • According to the latest figures from Q2 2025, Crinetics Pharmaceuticals' Gains from Investment Securities is -$4.1 million, which was down 201.02% from $4.1 million recorded in Q1 2025.
  • Crinetics Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $72.2 million during Q4 2024, with a 5-year trough of -$13.8 million in Q2 2024.
  • In the last 3 years, Crinetics Pharmaceuticals' Gains from Investment Securities had a median value of $2.4 million in 2023 and averaged $13.0 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first spiked by 36,591.13% in 2022, then tumbled by 2,077.43% in 2024.
  • Crinetics Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $5.1 million in 2021, then crashed by 94.13% to $300,000 in 2022, then slumped by 336.00% to -$708,000 in 2023, then soared by 10,290.82% to $72.2 million in 2024, then surged by 70.08% to -$4.1 million in 2025.
  • Its Gains from Investment Securities was -$4.1 million in Q2 2025, compared to $4.1 million in Q1 2025 and $72.2 million in Q4 2024.